← 홈

ADC · HER2

142개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-14 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 142개
ADCSHOTFDACuratedFDABiologicDaiichi SankyoDXd (topo-I inhibitor)Approved

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201)

HER2+ breast cancer, HER2-low, gastric · HER2

#HER2#ADC#Approved#FDA승인#바이오모아추천+5
효능 ORR 79.7%임상시험 215상태 APPROVED
ADCSHOTFDACuratedFDABiologicRocheMMAE (maytansinoid)Approved

ado-trastuzumab emtansine (Kadcyla, T-DM1, ado-trastuzumab emtansine / T-DM1)

HER2+ breast cancer · HER2

#HER2#ADC#Approved#FDA승인#바이오모아추천+5
효능 ORR 80%임상시험 159상태 APPROVED
ADCSHOTFDACuratedFDABiologicRemeGenMMAEApproved

disitamab vedotin (Disitamab Vedotin, RC48)

HER2+ urothelial, gastric, breast · HER2

#HER2#ADC#Approved#FDA승인#바이오모아추천+5
효능 ORR 50%임상시험 146상태 ACTIVE
ADCSFDAFDABiologicstaleDaiichi SankyoPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Fam-Trastuzumab Deruxtecan-Nxki)

HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer · HER2

#HER2#ADC#Phase2#FDA승인#항체약물접합체+4
효능 ORR 71.7%임상시험 23상태 RECRUITING
ADCBHotBiologicNCIC Clinical Trials Groupvedotin, 120 mg intr…Phase 3

Epirubicin (Epirubicin)

Breast Cancer · HER2

#HER2#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 62.7%임상시험 108상태 RECRUITING
ADCSHotBiologicRocheDM1 via butelase-1 with ABD…Approved

trastuzumab (Herceptin, Trastuzumab Emtansine)

HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer · Metastatic Salivary Gland Carcinoma

#MetastaticSalivaryGlandCarcinoma#ADC#Approved#인기#항체약물접합체+5
효능 ORR 69.7%임상시험 106상태 RECRUITING
ADCCBiologicEli Lilly and CompanyPhase 2

Abemaciclib (Abemaciclib)

Advanced Cancer; Metastatic Melanoma · HER2

#HER2#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 32.9%임상시험 77상태 RECRUITING
ADCCBiologicRemeGenvedotin plus PD-1 blockade …Phase 3

RC48 (Disitamab Vedotin, Disitamab Vedotin (RC48))

HER2 + Breast Cancer · mCRPC

#mCRPC#ADC#Phase3#인기#항체약물접합체+5
임상시험 76상태 RECRUITING
ADCBBiologicTheRas, Inc., dPhase 2

mFOLFOX6 (mFOLFOX6)

Non-Small Cell Lung Cancer; NSCLC · HER2

#HER2#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 63.64%임상시험 71상태 RECRUITING
ADCBiologicRocheDM1 via butelase-1 with ABD…Phase 2

trastuzumab (Herceptin, Ado-trastuzumab, Ado-trastuzumab (T) emtansine (T-DM1))

Salivary Gland Cancer; HER2 Gene Mutation · HER2

#HER2#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 74.1%임상시험 67상태 RECRUITING
ADCBiologicRemeGenvedotin plus PD-1 blockade …Phase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin(RC48) Plus Tratuzumab)

HER2-positive Gastric Cancer; HER2-positive Gastroesophageal Junction Adenocarcinoma · HER2

#HER2#ADC#Phase2#인기#항체약물접합체+5
임상시험 66상태 RECRUITING
ADCBiologicDaiichi SankyoDM1) and trastuzumab deruxt…Phase 3

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201)

Breast Cancer; HER2-positive Breast Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 65.8%임상시험 66상태 RECRUITING
ADCBiologicChia Tai Tianqing Pharmaceutica…Deruxtecan in Patients With…Phase 3

Taxane (Taxane)

HER2-negative Breast Cancer; Advanced Breast Cancer · HER2

#HER2#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 36%임상시험 64상태 RECRUITING
ADCBBiologicShanghai Junshi Bioscience Co.,…Phase 2

XELOX (XELOX)

Metastatic HER2 Positive Gastroesophageal Junction Cancer · HER2

#HER2#ADC#Phase2#인기#항체약물접합체+3
효능 ORR 47%임상시험 64상태 RECRUITING
ADCBiologicSanofireleasePhase 2

Anthracycline (Anthracycline)

HER2-negative Breast Cancer; Advanced Breast Cancer · HER2

#HER2#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 95%임상시험 63상태 RECRUITING
ADCBiologicAstraZenecaPhase 2

Goserelin (Goserelin)

Breast Cancer · HER2

#HER2#ADC#Phase2#인기#항체약물접합체+3
효능 ORR 31%임상시험 62상태 RECRUITING
ADCBiologicSuzhou Suncadia Biopharmaceutic…rezetecanPhase 3

SHR-A1811 (SHR-A1811)

Breast Cancer; HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase3#인기#항체약물접합체+5
임상시험 62상태 RECRUITING
ADCBiologicQuantumLeap Healthcare Collabor…Phase 2

Standard Therapy (Standard Therapy)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 9%임상시험 62상태 RECRUITING
ADCBiologicRelmada Therapeutics, Inc.deruxtecan improved objecti…Phase 2

Control treatment arm (Control treatment arm)

Hormone Receptor(HR)-Positive, Low HER2 Advanced Breast Cancer Patients (HER2 IHC 1+ or 2+ & ISH Negative) · HER2

#HER2#ADC#Phase2#인기#항체약물접합체+5
임상시험 61상태 RECRUITING
ADCBiologicBioMérieuxderuxtecan plus fluoropyrim…Phase 2

Experimental treatment arm (Experimental treatment arm)

Hormone Receptor(HR)-Positive, Low HER2 Advanced Breast Cancer Patients (HER2 IHC 1+ or 2+ & ISH Negative) · HER2

#HER2#ADC#Phase2#인기#항체약물접합체+5
임상시험 61상태 RECRUITING

1 / 8 페이지

← 이전다음 →